Journal article
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
- Abstract:
-
Background: Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint. Methods: In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previous...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 553.8KB)
-
- Publisher copy:
- 10.1016/S0140-6736(13)61501-9
Authors
Funding
National Institute for Health Research
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Journal website
- Volume:
- 382
- Issue:
- 9900
- Pages:
- 1258-1267
- Publication date:
- 2013-01-01
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Source identifiers:
-
415330
Item Description
- Language:
- English
- UUID:
-
uuid:06121ca7-8e18-4e11-864a-4aa0255262e1
- Local pid:
- pubs:415330
- Deposit date:
- 2014-08-29
Terms of use
- Copyright holder:
- Chakravarthy et al
- Copyright date:
- 2013
- Notes:
-
Copyright © Chakravarthy et al.
Open Access article distributed
under the terms of CC BY-NC-SA. Open Access funded by Department of Health UK.
If you are the owner of this record, you can report an update to it here: Report update to this record